AIDS Issues: Hearings Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, First Session, on Research and Treatment for Acquired Immune Deficiency Syndrome, July 22, 1985; Protection of Confidentiality of Records of Research Subjects and Blood Donors, July 29, 1985; Cost of AIDS Care and who is Going to Pay, November 1, 1985, Volume 4U.S. Government Printing Office, 1985 - 357 pages |
From inside the book
Results 1-5 of 69
Page 1
... budget had little room for basic research even on the virus , much less on treatment for the disease it causes . I am happy to say , however , that on ( 1 ) RESEARCH AND TREATMENT FOR ACQUIRED IMMUNE DEFICIENCY SYNDROME.
... budget had little room for basic research even on the virus , much less on treatment for the disease it causes . I am happy to say , however , that on ( 1 ) RESEARCH AND TREATMENT FOR ACQUIRED IMMUNE DEFICIENCY SYNDROME.
Page 20
... reverse transcriptase . The drug was found to be a potent inhibitor of HTLV - III replica- tion , and the cell - killing caused by this replication , in vitro . Since this drug had been used in human beings for decades 20.
... reverse transcriptase . The drug was found to be a potent inhibitor of HTLV - III replica- tion , and the cell - killing caused by this replication , in vitro . Since this drug had been used in human beings for decades 20.
Page 32
... caused by this replication ) in vitro . Since this drug had been used in human beings for decades as an anti - parasitic agent , data were available on acceptable dose regimens and information on its known toxicity in humans had been ...
... caused by this replication ) in vitro . Since this drug had been used in human beings for decades as an anti - parasitic agent , data were available on acceptable dose regimens and information on its known toxicity in humans had been ...
Page 36
... cause a minor reduction in Kaposi's sarcoma tumors in patients with AIDS . Neither of these effects by themselves , however , appear to provide a significant clinical improvement in the overall clinical status of the patient with AIDS ...
... cause a minor reduction in Kaposi's sarcoma tumors in patients with AIDS . Neither of these effects by themselves , however , appear to provide a significant clinical improvement in the overall clinical status of the patient with AIDS ...
Page 39
... cause of the problem , it may substantially improve the quality of life for the patient . Pneumocystis carinii is a protozoa which causes serious pneumonia in at least 60 percent of patients with AIDS . There are two drugs currently ...
... cause of the problem , it may substantially improve the quality of life for the patient . Pneumocystis carinii is a protozoa which causes serious pneumonia in at least 60 percent of patients with AIDS . There are two drugs currently ...
Other editions - View all
Common terms and phrases
additional AIDS epidemic AIDS patients AIDS victims AIDS virus American antibody test antiviral agents Association Belle Glade blood and plasma blood banks blood or plasma blood products Blue Cross cells Chairman clinical confidentiality cost coverage DANNEMEYER diagnosis disability disclosure donate blood drug eligible ELISA employers estimated evaluation facilities factor IX factor VIII Federal funding Glades General Hospital health insurance hemophilia hospital HTLV-III antibody HTLV-III virus immune globulin increased risk individuals infected Kaposi's sarcoma LEHNHARD lymphadenopathy Medicaid Medicare million NIELSON Office of Biologics patients with AIDS percent persons plasma plasma collection plasma derivatives plasmapheresis positive potential present problem procedures programs protect Public Health Service questions reactive retrovirus risk groups SCHEUER screening sexual Source Plasma specific studies Subcommittee suramin Syndrome AIDS test results therapy tion transfusion trials viral WACHS WAXMAN Western blot York City
Popular passages
Page 171 - Records of the identity, diagnosis, prognosis, or treatment of any patient which are maintained in connection with the performance of any drug abuse prevention function...
Page 171 - ... conducted, regulated, or directly or indirectly assisted by any department or agency of the United States shall, except as provided in subsection (c), be confidential and be disclosed only for the purposes and under the circumstances expressly authorized under subsection (b) of this section.
Page 166 - An IRB may waive the requirement for the investigator to obtain a signed consent form for some or all subjects if it finds either: (1) That the only record linking the subject and the research would be the consent document and the principal risk would be potential harm resulting from a breach of confidentiality. Each subject will be asked whether the subject wants documentation linking the subject with...
Page 159 - Consistent with the recommendations of the American Red Cross, the American Association of Blood Banks, the Council of Community Blood Centers, the...
Page 165 - A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject; (5) A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained...
Page 166 - When appropriate, the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects. (7) When appropriate, there are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.
Page 155 - DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville...
Page 178 - In addition, three major organizations dedicated to the development of high standards of donor protection and blood transfusion therapy — the American Association of Blood Banks, the American Red Cross, and the Council of Community Blood Centers...
Page 223 - The White House 1600 Pennsylvania Avenue NW Washington, DC 20500 Dear Mr. President: I am...
Page 150 - HTLV-III antibody should be offered to persons who may have been infected as a result of their contact with seropositive individuals (eg, sexual partners, persons with whom needles have been shared, infants born to seropositive mothers).